An open label study of the safety and efficacy of a single dose of weekly chloroquine and azithromycin administered for malaria prophylaxis in healthy adults challenged with 7G8 chloroquine-resistant Plasmodium falciparum in a controlled human malaria infection model
Background Malaria remains the top infectious disease threat facing the U.S. military in many forward operating environments. Compliance with malaria chemoprophylaxis remains a critical component in preventing malaria in the deployed Service Member. Studies of previous military operations show that...
Saved in:
| Published in | Malaria journal Vol. 19; no. 1; pp. 336 - 14 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
London
BioMed Central
16.09.2020
BioMed Central Ltd BMC |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1475-2875 1475-2875 |
| DOI | 10.1186/s12936-020-03409-z |
Cover
| Abstract | Background
Malaria remains the top infectious disease threat facing the U.S. military in many forward operating environments. Compliance with malaria chemoprophylaxis remains a critical component in preventing malaria in the deployed Service Member. Studies of previous military operations show that compliance is consistently higher with weekly
versus
daily dosing regimens. Current FDA approved weekly chemoprophylaxis options have contraindications that can limit prescribing. The combination of chloroquine (CQ) with azithromycin (AZ) has previously been shown to be an efficacious treatment option for malaria, has pharmacokinetics compatible with weekly dosing, and has shown synergy when combined in vitro.
Methods
In this open label study, 18 healthy volunteers, aged 18–50 years (inclusive), were randomly assigned to receive either 300 mg CQ or 300 mg CQ and 2 gm azithromycin (CQAZ) of directly observed therapy, weekly for 3 weeks prior to undergoing mosquito bite challenge with chloroquine-resistant
Plasmodium falciparum
. Volunteers that remained asymptomatic and had no evidence of parasitaemia continued to receive weekly post-exposure chemoprophylaxis for 3 weeks following malaria challenge. The primary endpoint was the number of volunteers that remained asymptomatic and had no evidence of parasitaemia 28 days after the malaria challenge.
Results
All 6 (100%) volunteers randomized to the CQ control group became symptomatic with parasitaemia during the 28-day post-challenge period. Only 1/12 (8.3%) of volunteers in the CQAZ group developed symptoms and parasitaemia during the 28-day post-challenge period. However, after chemoprophylaxis was discontinued an additional 6 volunteers developed parasitaemia between days 28–41 after challenge, with 4 of 6 experiencing symptoms. 80% of subjects in the CQAZ group experienced treatment related gastrointestinal adverse events (including 13% that experienced severe nausea) compared to 38% in the CQ group. A comparison of the pharmacokinetics in the CQAZ group demonstrated higher azithromycin Cmax (p = 0.03) and AUC (p = 0.044) levels in those volunteers who never became parasitaemic compared to those who did.
Conclusion
Given the high rate of side effects and poor efficacy when administered for 3 weeks before and after challenge, the combination of weekly chloroquine and azithromycin is a suboptimal regimen combination for weekly malaria chemoprophylaxis.
Trial registration
ClinicalTrials.gov NCT03278808 |
|---|---|
| AbstractList | Malaria remains the top infectious disease threat facing the U.S. military in many forward operating environments. Compliance with malaria chemoprophylaxis remains a critical component in preventing malaria in the deployed Service Member. Studies of previous military operations show that compliance is consistently higher with weekly versus daily dosing regimens. Current FDA approved weekly chemoprophylaxis options have contraindications that can limit prescribing. The combination of chloroquine (CQ) with azithromycin (AZ) has previously been shown to be an efficacious treatment option for malaria, has pharmacokinetics compatible with weekly dosing, and has shown synergy when combined in vitro. In this open label study, 18 healthy volunteers, aged 18-50 years (inclusive), were randomly assigned to receive either 300 mg CQ or 300 mg CQ and 2 gm azithromycin (CQAZ) of directly observed therapy, weekly for 3 weeks prior to undergoing mosquito bite challenge with chloroquine-resistant Plasmodium falciparum. Volunteers that remained asymptomatic and had no evidence of parasitaemia continued to receive weekly post-exposure chemoprophylaxis for 3 weeks following malaria challenge. The primary endpoint was the number of volunteers that remained asymptomatic and had no evidence of parasitaemia 28 days after the malaria challenge. All 6 (100%) volunteers randomized to the CQ control group became symptomatic with parasitaemia during the 28-day post-challenge period. Only 1/12 (8.3%) of volunteers in the CQAZ group developed symptoms and parasitaemia during the 28-day post-challenge period. However, after chemoprophylaxis was discontinued an additional 6 volunteers developed parasitaemia between days 28-41 after challenge, with 4 of 6 experiencing symptoms. 80% of subjects in the CQAZ group experienced treatment related gastrointestinal adverse events (including 13% that experienced severe nausea) compared to 38% in the CQ group. A comparison of the pharmacokinetics in the CQAZ group demonstrated higher azithromycin Cmax (p = 0.03) and AUC (p = 0.044) levels in those volunteers who never became parasitaemic compared to those who did. Given the high rate of side effects and poor efficacy when administered for 3 weeks before and after challenge, the combination of weekly chloroquine and azithromycin is a suboptimal regimen combination for weekly malaria chemoprophylaxis. Malaria remains the top infectious disease threat facing the U.S. military in many forward operating environments. Compliance with malaria chemoprophylaxis remains a critical component in preventing malaria in the deployed Service Member. Studies of previous military operations show that compliance is consistently higher with weekly versus daily dosing regimens. Current FDA approved weekly chemoprophylaxis options have contraindications that can limit prescribing. The combination of chloroquine (CQ) with azithromycin (AZ) has previously been shown to be an efficacious treatment option for malaria, has pharmacokinetics compatible with weekly dosing, and has shown synergy when combined in vitro.BACKGROUNDMalaria remains the top infectious disease threat facing the U.S. military in many forward operating environments. Compliance with malaria chemoprophylaxis remains a critical component in preventing malaria in the deployed Service Member. Studies of previous military operations show that compliance is consistently higher with weekly versus daily dosing regimens. Current FDA approved weekly chemoprophylaxis options have contraindications that can limit prescribing. The combination of chloroquine (CQ) with azithromycin (AZ) has previously been shown to be an efficacious treatment option for malaria, has pharmacokinetics compatible with weekly dosing, and has shown synergy when combined in vitro.In this open label study, 18 healthy volunteers, aged 18-50 years (inclusive), were randomly assigned to receive either 300 mg CQ or 300 mg CQ and 2 gm azithromycin (CQAZ) of directly observed therapy, weekly for 3 weeks prior to undergoing mosquito bite challenge with chloroquine-resistant Plasmodium falciparum. Volunteers that remained asymptomatic and had no evidence of parasitaemia continued to receive weekly post-exposure chemoprophylaxis for 3 weeks following malaria challenge. The primary endpoint was the number of volunteers that remained asymptomatic and had no evidence of parasitaemia 28 days after the malaria challenge.METHODSIn this open label study, 18 healthy volunteers, aged 18-50 years (inclusive), were randomly assigned to receive either 300 mg CQ or 300 mg CQ and 2 gm azithromycin (CQAZ) of directly observed therapy, weekly for 3 weeks prior to undergoing mosquito bite challenge with chloroquine-resistant Plasmodium falciparum. Volunteers that remained asymptomatic and had no evidence of parasitaemia continued to receive weekly post-exposure chemoprophylaxis for 3 weeks following malaria challenge. The primary endpoint was the number of volunteers that remained asymptomatic and had no evidence of parasitaemia 28 days after the malaria challenge.All 6 (100%) volunteers randomized to the CQ control group became symptomatic with parasitaemia during the 28-day post-challenge period. Only 1/12 (8.3%) of volunteers in the CQAZ group developed symptoms and parasitaemia during the 28-day post-challenge period. However, after chemoprophylaxis was discontinued an additional 6 volunteers developed parasitaemia between days 28-41 after challenge, with 4 of 6 experiencing symptoms. 80% of subjects in the CQAZ group experienced treatment related gastrointestinal adverse events (including 13% that experienced severe nausea) compared to 38% in the CQ group. A comparison of the pharmacokinetics in the CQAZ group demonstrated higher azithromycin Cmax (p = 0.03) and AUC (p = 0.044) levels in those volunteers who never became parasitaemic compared to those who did.RESULTSAll 6 (100%) volunteers randomized to the CQ control group became symptomatic with parasitaemia during the 28-day post-challenge period. Only 1/12 (8.3%) of volunteers in the CQAZ group developed symptoms and parasitaemia during the 28-day post-challenge period. However, after chemoprophylaxis was discontinued an additional 6 volunteers developed parasitaemia between days 28-41 after challenge, with 4 of 6 experiencing symptoms. 80% of subjects in the CQAZ group experienced treatment related gastrointestinal adverse events (including 13% that experienced severe nausea) compared to 38% in the CQ group. A comparison of the pharmacokinetics in the CQAZ group demonstrated higher azithromycin Cmax (p = 0.03) and AUC (p = 0.044) levels in those volunteers who never became parasitaemic compared to those who did.Given the high rate of side effects and poor efficacy when administered for 3 weeks before and after challenge, the combination of weekly chloroquine and azithromycin is a suboptimal regimen combination for weekly malaria chemoprophylaxis. Trial registration ClinicalTrials.gov NCT03278808.CONCLUSIONGiven the high rate of side effects and poor efficacy when administered for 3 weeks before and after challenge, the combination of weekly chloroquine and azithromycin is a suboptimal regimen combination for weekly malaria chemoprophylaxis. Trial registration ClinicalTrials.gov NCT03278808. Background Malaria remains the top infectious disease threat facing the U.S. military in many forward operating environments. Compliance with malaria chemoprophylaxis remains a critical component in preventing malaria in the deployed Service Member. Studies of previous military operations show that compliance is consistently higher with weekly versus daily dosing regimens. Current FDA approved weekly chemoprophylaxis options have contraindications that can limit prescribing. The combination of chloroquine (CQ) with azithromycin (AZ) has previously been shown to be an efficacious treatment option for malaria, has pharmacokinetics compatible with weekly dosing, and has shown synergy when combined in vitro. Methods In this open label study, 18 healthy volunteers, aged 18–50 years (inclusive), were randomly assigned to receive either 300 mg CQ or 300 mg CQ and 2 gm azithromycin (CQAZ) of directly observed therapy, weekly for 3 weeks prior to undergoing mosquito bite challenge with chloroquine-resistant Plasmodium falciparum . Volunteers that remained asymptomatic and had no evidence of parasitaemia continued to receive weekly post-exposure chemoprophylaxis for 3 weeks following malaria challenge. The primary endpoint was the number of volunteers that remained asymptomatic and had no evidence of parasitaemia 28 days after the malaria challenge. Results All 6 (100%) volunteers randomized to the CQ control group became symptomatic with parasitaemia during the 28-day post-challenge period. Only 1/12 (8.3%) of volunteers in the CQAZ group developed symptoms and parasitaemia during the 28-day post-challenge period. However, after chemoprophylaxis was discontinued an additional 6 volunteers developed parasitaemia between days 28–41 after challenge, with 4 of 6 experiencing symptoms. 80% of subjects in the CQAZ group experienced treatment related gastrointestinal adverse events (including 13% that experienced severe nausea) compared to 38% in the CQ group. A comparison of the pharmacokinetics in the CQAZ group demonstrated higher azithromycin Cmax (p = 0.03) and AUC (p = 0.044) levels in those volunteers who never became parasitaemic compared to those who did. Conclusion Given the high rate of side effects and poor efficacy when administered for 3 weeks before and after challenge, the combination of weekly chloroquine and azithromycin is a suboptimal regimen combination for weekly malaria chemoprophylaxis. Trial registration ClinicalTrials.gov NCT03278808 Background Malaria remains the top infectious disease threat facing the U.S. military in many forward operating environments. Compliance with malaria chemoprophylaxis remains a critical component in preventing malaria in the deployed Service Member. Studies of previous military operations show that compliance is consistently higher with weekly versus daily dosing regimens. Current FDA approved weekly chemoprophylaxis options have contraindications that can limit prescribing. The combination of chloroquine (CQ) with azithromycin (AZ) has previously been shown to be an efficacious treatment option for malaria, has pharmacokinetics compatible with weekly dosing, and has shown synergy when combined in vitro. Methods In this open label study, 18 healthy volunteers, aged 18–50 years (inclusive), were randomly assigned to receive either 300 mg CQ or 300 mg CQ and 2 gm azithromycin (CQAZ) of directly observed therapy, weekly for 3 weeks prior to undergoing mosquito bite challenge with chloroquine-resistant Plasmodium falciparum. Volunteers that remained asymptomatic and had no evidence of parasitaemia continued to receive weekly post-exposure chemoprophylaxis for 3 weeks following malaria challenge. The primary endpoint was the number of volunteers that remained asymptomatic and had no evidence of parasitaemia 28 days after the malaria challenge. Results All 6 (100%) volunteers randomized to the CQ control group became symptomatic with parasitaemia during the 28-day post-challenge period. Only 1/12 (8.3%) of volunteers in the CQAZ group developed symptoms and parasitaemia during the 28-day post-challenge period. However, after chemoprophylaxis was discontinued an additional 6 volunteers developed parasitaemia between days 28–41 after challenge, with 4 of 6 experiencing symptoms. 80% of subjects in the CQAZ group experienced treatment related gastrointestinal adverse events (including 13% that experienced severe nausea) compared to 38% in the CQ group. A comparison of the pharmacokinetics in the CQAZ group demonstrated higher azithromycin Cmax (p = 0.03) and AUC (p = 0.044) levels in those volunteers who never became parasitaemic compared to those who did. Conclusion Given the high rate of side effects and poor efficacy when administered for 3 weeks before and after challenge, the combination of weekly chloroquine and azithromycin is a suboptimal regimen combination for weekly malaria chemoprophylaxis. Trial registration ClinicalTrials.gov NCT03278808 Malaria remains the top infectious disease threat facing the U.S. military in many forward operating environments. Compliance with malaria chemoprophylaxis remains a critical component in preventing malaria in the deployed Service Member. Studies of previous military operations show that compliance is consistently higher with weekly versus daily dosing regimens. Current FDA approved weekly chemoprophylaxis options have contraindications that can limit prescribing. The combination of chloroquine (CQ) with azithromycin (AZ) has previously been shown to be an efficacious treatment option for malaria, has pharmacokinetics compatible with weekly dosing, and has shown synergy when combined in vitro. In this open label study, 18 healthy volunteers, aged 18-50 years (inclusive), were randomly assigned to receive either 300 mg CQ or 300 mg CQ and 2 gm azithromycin (CQAZ) of directly observed therapy, weekly for 3 weeks prior to undergoing mosquito bite challenge with chloroquine-resistant Plasmodium falciparum. Volunteers that remained asymptomatic and had no evidence of parasitaemia continued to receive weekly post-exposure chemoprophylaxis for 3 weeks following malaria challenge. The primary endpoint was the number of volunteers that remained asymptomatic and had no evidence of parasitaemia 28 days after the malaria challenge. All 6 (100%) volunteers randomized to the CQ control group became symptomatic with parasitaemia during the 28-day post-challenge period. Only 1/12 (8.3%) of volunteers in the CQAZ group developed symptoms and parasitaemia during the 28-day post-challenge period. However, after chemoprophylaxis was discontinued an additional 6 volunteers developed parasitaemia between days 28-41 after challenge, with 4 of 6 experiencing symptoms. 80% of subjects in the CQAZ group experienced treatment related gastrointestinal adverse events (including 13% that experienced severe nausea) compared to 38% in the CQ group. A comparison of the pharmacokinetics in the CQAZ group demonstrated higher azithromycin Cmax (p = 0.03) and AUC (p = 0.044) levels in those volunteers who never became parasitaemic compared to those who did. Given the high rate of side effects and poor efficacy when administered for 3 weeks before and after challenge, the combination of weekly chloroquine and azithromycin is a suboptimal regimen combination for weekly malaria chemoprophylaxis. Trial registration ClinicalTrials.gov NCT03278808. Background Malaria remains the top infectious disease threat facing the U.S. military in many forward operating environments. Compliance with malaria chemoprophylaxis remains a critical component in preventing malaria in the deployed Service Member. Studies of previous military operations show that compliance is consistently higher with weekly versus daily dosing regimens. Current FDA approved weekly chemoprophylaxis options have contraindications that can limit prescribing. The combination of chloroquine (CQ) with azithromycin (AZ) has previously been shown to be an efficacious treatment option for malaria, has pharmacokinetics compatible with weekly dosing, and has shown synergy when combined in vitro. Methods In this open label study, 18 healthy volunteers, aged 18-50 years (inclusive), were randomly assigned to receive either 300 mg CQ or 300 mg CQ and 2 gm azithromycin (CQAZ) of directly observed therapy, weekly for 3 weeks prior to undergoing mosquito bite challenge with chloroquine-resistant Plasmodium falciparum. Volunteers that remained asymptomatic and had no evidence of parasitaemia continued to receive weekly post-exposure chemoprophylaxis for 3 weeks following malaria challenge. The primary endpoint was the number of volunteers that remained asymptomatic and had no evidence of parasitaemia 28 days after the malaria challenge. Results All 6 (100%) volunteers randomized to the CQ control group became symptomatic with parasitaemia during the 28-day post-challenge period. Only 1/12 (8.3%) of volunteers in the CQAZ group developed symptoms and parasitaemia during the 28-day post-challenge period. However, after chemoprophylaxis was discontinued an additional 6 volunteers developed parasitaemia between days 28-41 after challenge, with 4 of 6 experiencing symptoms. 80% of subjects in the CQAZ group experienced treatment related gastrointestinal adverse events (including 13% that experienced severe nausea) compared to 38% in the CQ group. A comparison of the pharmacokinetics in the CQAZ group demonstrated higher azithromycin Cmax (p = 0.03) and AUC (p = 0.044) levels in those volunteers who never became parasitaemic compared to those who did. Conclusion Given the high rate of side effects and poor efficacy when administered for 3 weeks before and after challenge, the combination of weekly chloroquine and azithromycin is a suboptimal regimen combination for weekly malaria chemoprophylaxis. Trial registration ClinicalTrials.gov NCT03278808 Keywords: Malaria chemoprophylaxis, Azithromycin, Chloroquine, Controlled human malaria infection Abstract Background Malaria remains the top infectious disease threat facing the U.S. military in many forward operating environments. Compliance with malaria chemoprophylaxis remains a critical component in preventing malaria in the deployed Service Member. Studies of previous military operations show that compliance is consistently higher with weekly versus daily dosing regimens. Current FDA approved weekly chemoprophylaxis options have contraindications that can limit prescribing. The combination of chloroquine (CQ) with azithromycin (AZ) has previously been shown to be an efficacious treatment option for malaria, has pharmacokinetics compatible with weekly dosing, and has shown synergy when combined in vitro. Methods In this open label study, 18 healthy volunteers, aged 18–50 years (inclusive), were randomly assigned to receive either 300 mg CQ or 300 mg CQ and 2 gm azithromycin (CQAZ) of directly observed therapy, weekly for 3 weeks prior to undergoing mosquito bite challenge with chloroquine-resistant Plasmodium falciparum. Volunteers that remained asymptomatic and had no evidence of parasitaemia continued to receive weekly post-exposure chemoprophylaxis for 3 weeks following malaria challenge. The primary endpoint was the number of volunteers that remained asymptomatic and had no evidence of parasitaemia 28 days after the malaria challenge. Results All 6 (100%) volunteers randomized to the CQ control group became symptomatic with parasitaemia during the 28-day post-challenge period. Only 1/12 (8.3%) of volunteers in the CQAZ group developed symptoms and parasitaemia during the 28-day post-challenge period. However, after chemoprophylaxis was discontinued an additional 6 volunteers developed parasitaemia between days 28–41 after challenge, with 4 of 6 experiencing symptoms. 80% of subjects in the CQAZ group experienced treatment related gastrointestinal adverse events (including 13% that experienced severe nausea) compared to 38% in the CQ group. A comparison of the pharmacokinetics in the CQAZ group demonstrated higher azithromycin Cmax (p = 0.03) and AUC (p = 0.044) levels in those volunteers who never became parasitaemic compared to those who did. Conclusion Given the high rate of side effects and poor efficacy when administered for 3 weeks before and after challenge, the combination of weekly chloroquine and azithromycin is a suboptimal regimen combination for weekly malaria chemoprophylaxis. Trial registration ClinicalTrials.gov NCT03278808 |
| ArticleNumber | 336 |
| Audience | Academic |
| Author | Waterman, Paige Morrison, Meshell Sedegah, Martha Selig, Daniel Tosh, Donna Poon, Lucas Twomey, Patrick Duncan, Elizabeth H. Moon, James E. Kreishman-Deitrick, Mara Cicatelli, Susan Bennett, Jason Sousa, Jason Hutter, Jack Livezey, Jeffrey Vuong, Chau Hamer, Melinda DeLuca, Jesse Sikaffy, April Mills, Kristin Oliver, Thomas Lee, Christine |
| Author_xml | – sequence: 1 givenname: Jeffrey orcidid: 0000-0001-9748-095X surname: Livezey fullname: Livezey, Jeffrey email: jeffrey.livezey@usuhs.edu organization: Uniformed Services University of the Health Sciences, 4301 Jones Bridge Rd – sequence: 2 givenname: Patrick surname: Twomey fullname: Twomey, Patrick organization: Walter Reed Army Institute of Research – sequence: 3 givenname: Meshell surname: Morrison fullname: Morrison, Meshell organization: Walter Reed Army Institute of Research – sequence: 4 givenname: Susan surname: Cicatelli fullname: Cicatelli, Susan organization: Walter Reed Army Institute of Research – sequence: 5 givenname: Elizabeth H. surname: Duncan fullname: Duncan, Elizabeth H. organization: Walter Reed Army Institute of Research – sequence: 6 givenname: Melinda surname: Hamer fullname: Hamer, Melinda organization: Walter Reed Army Institute of Research – sequence: 7 givenname: Christine surname: Lee fullname: Lee, Christine organization: Walter Reed Army Institute of Research – sequence: 8 givenname: Jack surname: Hutter fullname: Hutter, Jack organization: Walter Reed Army Institute of Research – sequence: 9 givenname: Kristin surname: Mills fullname: Mills, Kristin organization: Walter Reed Army Institute of Research – sequence: 10 givenname: Jesse surname: DeLuca fullname: DeLuca, Jesse organization: Walter Reed Army Institute of Research – sequence: 11 givenname: Lucas surname: Poon fullname: Poon, Lucas organization: Walter Reed Army Institute of Research – sequence: 12 givenname: Daniel surname: Selig fullname: Selig, Daniel organization: Walter Reed Army Institute of Research – sequence: 13 givenname: Chau surname: Vuong fullname: Vuong, Chau organization: Walter Reed Army Institute of Research – sequence: 14 givenname: Jason surname: Sousa fullname: Sousa, Jason organization: Walter Reed Army Institute of Research – sequence: 15 givenname: Thomas surname: Oliver fullname: Oliver, Thomas organization: Uniformed Services University of the Health Sciences, 4301 Jones Bridge Rd – sequence: 16 givenname: Jason surname: Bennett fullname: Bennett, Jason organization: Walter Reed Army Institute of Research – sequence: 17 givenname: James E. surname: Moon fullname: Moon, James E. organization: Walter Reed Army Institute of Research – sequence: 18 givenname: April surname: Sikaffy fullname: Sikaffy, April organization: Walter Reed Army Institute of Research – sequence: 19 givenname: Martha surname: Sedegah fullname: Sedegah, Martha organization: Naval Medical Research Center – sequence: 20 givenname: Donna surname: Tosh fullname: Tosh, Donna organization: Walter Reed Army Institute of Research – sequence: 21 givenname: Mara surname: Kreishman-Deitrick fullname: Kreishman-Deitrick, Mara organization: Walter Reed Army Institute of Research – sequence: 22 givenname: Paige surname: Waterman fullname: Waterman, Paige organization: Walter Reed Army Institute of Research |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32938444$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9U0tv1DAQDqiIPuAPcECWuHBJcWzndUFaVVAqVYJD79HEHm9cHHuxE8rur8e7W_oSqnKINf4emS8zx9mB8w6z7F1BT4uiqT7FgrW8yimjOeWCtvnmZXZUiLrMWVOXBw_Oh9lxjNeUFnVTs9fZIU_ERghx9OJk4YhfoSMWerQkTrNaE6_JNCCJoHFaE3CKoNZGgtxdAYnGLS0S5SNuCzeIP-2ayMH64H_NxuGOAxszDcGPa2kcATUaZ-KEARXRPpARLAQDZBX8alhb-GMiSbgBwU5DMlWznWLSBGvRLRPpJqmR-rx56JMHjEkU3ER-WIijV2YeiQYrzQpCOm6difRuCj7pKDLMI7g7b-M0ysn4VPEK7ZvsVaJGfHv7Psmuvn65OvuWX34_vzhbXOayZGyT17pnlMue9y2retq0pYZaqr5vKtpr3tdtJTgT2KiKKaG0riRVui41o7rUBT_JLvayysN1twpmhLDuPJhuV_Bh2UGYjLTYoSoUV1XfNm0tKBNQsprrumpLKBrdQ9L6vNdazf2ISmLqFOwj0cc3zgzd0v_uatHyQtAk8PFWYBspxqkbTZRoLTj0c-yYELypW9a2CfrhCfTaz8GlpHaotml4Se9RS0gNpIR98pVb0W5R8aoVKZ4t6vQ_qPQoHE36X6hNqj8ivH_Y6F2H_yY5AdgeIIOPMaC-gxS0265Lt1-XLq1Lt1uXbpNIzROSNBNsJyJ9jrHPU_meGpNPGtBwn8YzrL8nADB1 |
| CitedBy_id | crossref_primary_10_1371_journal_pone_0253232 |
| Cites_doi | 10.1086/429343 10.1128/AAC.47.7.2199-2203.2003 10.4269/ajtmh.2006.74.407 10.1001/jama.293.2.212 10.1128/IAI.00479-17 10.1128/AAC.01771-17 10.1086/516281 10.1016/0035-9203(84)90114-7 10.15585/mmwr.ss6805a1 10.1074/jbc.M608615200 10.1128/AAC.01566-10 10.1186/1475-2875-13-458 10.4269/ajtmh.16-0332 10.4269/ajtmh.2012.11-0511 10.1128/AAC.46.8.2518-2524.2002 10.1086/656476 10.4269/ajtmh.15-0245 10.1086/515071 10.1001/jama.1994.03520050077034 10.3390/antibiotics3020109 10.4269/ajtmh.15-0004 10.1097/00007435-199403000-00010 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2020 COPYRIGHT 2020 BioMed Central Ltd. 2020. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: The Author(s) 2020 – notice: COPYRIGHT 2020 BioMed Central Ltd. – notice: 2020. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7SS 7U9 7X7 7XB 88E 8C1 8FI 8FJ 8FK ABUWG AEUYN AFKRA AZQEC BENPR C1K CCPQU DWQXO F1W FYUFA GHDGH H94 H95 H97 K9. L.G M0S M1P M7N PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
| DOI | 10.1186/s12936-020-03409-z |
| DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Entomology Abstracts (Full archive) Virology and AIDS Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Public Health Database Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central Environmental Sciences and Pollution Management ProQuest One Community College ProQuest Central Korea ASFA: Aquatic Sciences and Fisheries Abstracts Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts Aquatic Science & Fisheries Abstracts (ASFA) 1: Biological Sciences & Living Resources Aquatic Science & Fisheries Abstracts (ASFA) 3: Aquatic Pollution & Environmental Quality ProQuest Health & Medical Complete (Alumni) Aquatic Science & Fisheries Abstracts (ASFA) Professional ProQuest Health & Medical Collection Medical Database Algology Mycology and Protozoology Abstracts (Microbiology C) ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals (ND) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database Aquatic Science & Fisheries Abstracts (ASFA) Professional ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China Aquatic Science & Fisheries Abstracts (ASFA) 3: Aquatic Pollution & Environmental Quality Environmental Sciences and Pollution Management ProQuest Central ProQuest One Sustainability Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Algology Mycology and Protozoology Abstracts (Microbiology C) Health & Medical Research Collection AIDS and Cancer Research Abstracts Aquatic Science & Fisheries Abstracts (ASFA) 1: Biological Sciences & Living Resources ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Public Health Virology and AIDS Abstracts ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) Entomology Abstracts ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ASFA: Aquatic Sciences and Fisheries Abstracts ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic Publicly Available Content Database MEDLINE |
| Database_xml | – sequence: 1 dbid: C6C name: Springer Nature OA Free Journals url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 3 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 5 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Public Health |
| EISSN | 1475-2875 |
| EndPage | 14 |
| ExternalDocumentID | oai_doaj_org_article_ed1d3d6b98974024a5273f7695a18fba PMC7493140 A636947960 32938444 10_1186_s12936_020_03409_z |
| Genre | Randomized Controlled Trial Journal Article |
| GeographicLocations | United States Colombia Suriname United States--US India |
| GeographicLocations_xml | – name: United States – name: Suriname – name: Colombia – name: United States--US – name: India |
| GrantInformation_xml | – fundername: Congressionally Directed Medical Research Programs grantid: CDMRPL-16-0-PR141035A funderid: http://dx.doi.org/10.13039/100000090 – fundername: Congressionally Directed Medical Research Programs grantid: CDMRPL-16-0-PR141035A – fundername: ; grantid: CDMRPL-16-0-PR141035A |
| GroupedDBID | --- 0R~ 29M 2WC 53G 5VS 7X7 88E 8C1 8FI 8FJ AAFWJ AAJSJ AASML ABDBF ABUWG ACGFO ACGFS ACIHN ACMJI ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AEUYN AFKRA AFPKN AHBYD AHMBA AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CS3 DIK DU5 E3Z EAD EAP EAS EBD EBLON EBS ECGQY EMB EMK EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IHR INH INR ITC KQ8 M1P M48 M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PQQKQ PROAC PSQYO PUEGO RBZ RNS ROL RPM RSV SBL SOJ SV3 TR2 TUS U2A UKHRP W2D WOQ WOW XSB AAYXX ALIPV CITATION -A0 3V. ACRMQ ADINQ C24 CGR CUY CVF ECM EIF FRP NPM PMFND 7SS 7U9 7XB 8FK AZQEC C1K DWQXO F1W H94 H95 H97 K9. L.G M7N PKEHL PQEST PQUKI PRINS 7X8 5PM |
| ID | FETCH-LOGICAL-c522z-7fb203cb3b926b0895fa7cdbb860bf3b7964324e8d62d4dff6c0df75f20f5f13 |
| IEDL.DBID | M48 |
| ISSN | 1475-2875 |
| IngestDate | Wed Aug 27 01:32:14 EDT 2025 Thu Aug 21 13:40:56 EDT 2025 Thu Sep 04 19:13:56 EDT 2025 Fri Jul 25 07:08:40 EDT 2025 Tue Jun 17 21:38:22 EDT 2025 Tue Jun 10 20:50:41 EDT 2025 Thu Jan 02 22:57:39 EST 2025 Tue Jul 01 02:40:00 EDT 2025 Thu Apr 24 22:53:10 EDT 2025 Sat Sep 06 07:29:45 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Malaria chemoprophylaxis Controlled human malaria infection Chloroquine Azithromycin |
| Language | English |
| License | Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c522z-7fb203cb3b926b0895fa7cdbb860bf3b7964324e8d62d4dff6c0df75f20f5f13 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Undefined-3 |
| ORCID | 0000-0001-9748-095X |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.1186/s12936-020-03409-z |
| PMID | 32938444 |
| PQID | 2443988350 |
| PQPubID | 42600 |
| PageCount | 14 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_ed1d3d6b98974024a5273f7695a18fba pubmedcentral_primary_oai_pubmedcentral_nih_gov_7493140 proquest_miscellaneous_2443879299 proquest_journals_2443988350 gale_infotracmisc_A636947960 gale_infotracacademiconefile_A636947960 pubmed_primary_32938444 crossref_primary_10_1186_s12936_020_03409_z crossref_citationtrail_10_1186_s12936_020_03409_z springer_journals_10_1186_s12936_020_03409_z |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 20200916 |
| PublicationDateYYYYMMDD | 2020-09-16 |
| PublicationDate_xml | – month: 9 year: 2020 text: 20200916 day: 16 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | Malaria journal |
| PublicationTitleAbbrev | Malar J |
| PublicationTitleAlternate | Malar J |
| PublicationYear | 2020 |
| Publisher | BioMed Central BioMed Central Ltd BMC |
| Publisher_xml | – name: BioMed Central – name: BioMed Central Ltd – name: BMC |
| References | WR Taylor (3409_CR12) 1999; 28 3409_CR27 AB Sidhu (3409_CR5) 2007; 282 T Kobayashi (3409_CR22) 2015; 93 WR Taylor (3409_CR11) 2003; 47 3409_CR4 M Brisson (3409_CR17) 2012; 86 TR Burkot (3409_CR20) 1984; 78 DL Saunders (3409_CR3) 2015; 93 NA Kshirsagar (3409_CR15) 2017; 8 S Takahashi (3409_CR26) 2014; 3 JA Newton Jr (3409_CR18) 1994; 272 DI Stanisic (3409_CR28) 2017; 86 3409_CR1 C Ohrt (3409_CR7) 2002; 46 F Teuscher (3409_CR23) 2010; 202 M Duvalsaint (3409_CR24) 2018; 62 3409_CR16 I Sagara (3409_CR14) 2014; 13 WHO (3409_CR21) 2009 PJ Rosenthal (3409_CR6) 2016; 95 JA Cook (3409_CR9) 2006; 74 RS Kotwal (3409_CR19) 2005; 292 HH Handsfield (3409_CR25) 1994; 21 MR Pereira (3409_CR8) 2011; 55 KE Mace (3409_CR2) 2019; 68 SL Andersen (3409_CR10) 1998; 26 MW Dunne (3409_CR13) 2005; 191 |
| References_xml | – ident: 3409_CR4 – volume: 191 start-page: 1582 year: 2005 ident: 3409_CR13 publication-title: J Infect Dis doi: 10.1086/429343 – volume: 47 start-page: 2199 year: 2003 ident: 3409_CR11 publication-title: Antimicrob Agents Chemother. doi: 10.1128/AAC.47.7.2199-2203.2003 – volume: 74 start-page: 407 year: 2006 ident: 3409_CR9 publication-title: Am J Trop Med Hyg doi: 10.4269/ajtmh.2006.74.407 – volume: 8 start-page: 85 year: 2017 ident: 3409_CR15 publication-title: Res Rep Trop Med. – volume: 292 start-page: 212 year: 2005 ident: 3409_CR19 publication-title: JAMA doi: 10.1001/jama.293.2.212 – volume: 86 start-page: e00479-17 year: 2017 ident: 3409_CR28 publication-title: Infect Immun doi: 10.1128/IAI.00479-17 – volume: 62 start-page: e01771-17 year: 2018 ident: 3409_CR24 publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.01771-17 – ident: 3409_CR1 – ident: 3409_CR27 – volume: 26 start-page: 146 year: 1998 ident: 3409_CR10 publication-title: Clin Infect Dis doi: 10.1086/516281 – volume: 78 start-page: 339 year: 1984 ident: 3409_CR20 publication-title: Trans R Soc Trop Med Hyg doi: 10.1016/0035-9203(84)90114-7 – volume: 68 start-page: 1 year: 2019 ident: 3409_CR2 publication-title: MMWR Surveill Summ. doi: 10.15585/mmwr.ss6805a1 – volume: 282 start-page: 2494 year: 2007 ident: 3409_CR5 publication-title: J Biol Chem doi: 10.1074/jbc.M608615200 – ident: 3409_CR16 – volume: 55 start-page: 3115 year: 2011 ident: 3409_CR8 publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.01566-10 – start-page: 1 volume-title: Methods for surveillance of antimalarial drug efficacy year: 2009 ident: 3409_CR21 – volume: 13 start-page: 458 year: 2014 ident: 3409_CR14 publication-title: Malar J. doi: 10.1186/1475-2875-13-458 – volume: 95 start-page: 2 year: 2016 ident: 3409_CR6 publication-title: Am J Trop Med Hyg doi: 10.4269/ajtmh.16-0332 – volume: 86 start-page: 587 year: 2012 ident: 3409_CR17 publication-title: Am J Trop Med Hyg doi: 10.4269/ajtmh.2012.11-0511 – volume: 46 start-page: 2518 year: 2002 ident: 3409_CR7 publication-title: Antimicrob Agents Chemother. doi: 10.1128/AAC.46.8.2518-2524.2002 – volume: 202 start-page: 1362 year: 2010 ident: 3409_CR23 publication-title: J Infect Dis doi: 10.1086/656476 – volume: 93 start-page: 584 year: 2015 ident: 3409_CR3 publication-title: Am J Trop Med Hyg. doi: 10.4269/ajtmh.15-0245 – volume: 28 start-page: 74 year: 1999 ident: 3409_CR12 publication-title: Clin Infect Dis. doi: 10.1086/515071 – volume: 272 start-page: 397 year: 1994 ident: 3409_CR18 publication-title: JAMA doi: 10.1001/jama.1994.03520050077034 – volume: 3 start-page: 109 year: 2014 ident: 3409_CR26 publication-title: Antibiotics (Basel). doi: 10.3390/antibiotics3020109 – volume: 93 start-page: 99 issue: 3 Suppl year: 2015 ident: 3409_CR22 publication-title: Am J Trop Med Hyg doi: 10.4269/ajtmh.15-0004 – volume: 21 start-page: 107 year: 1994 ident: 3409_CR25 publication-title: Sex Transm Dis. doi: 10.1097/00007435-199403000-00010 |
| SSID | ssj0017872 |
| Score | 2.2781928 |
| Snippet | Background
Malaria remains the top infectious disease threat facing the U.S. military in many forward operating environments. Compliance with malaria... Malaria remains the top infectious disease threat facing the U.S. military in many forward operating environments. Compliance with malaria chemoprophylaxis... Background Malaria remains the top infectious disease threat facing the U.S. military in many forward operating environments. Compliance with malaria... Abstract Background Malaria remains the top infectious disease threat facing the U.S. military in many forward operating environments. Compliance with malaria... |
| SourceID | doaj pubmedcentral proquest gale pubmed crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 336 |
| SubjectTerms | Adult Antibiotics Antimalarials - adverse effects Aquatic insects Armed forces Azithromycin Azithromycin - adverse effects Biomedical and Life Sciences Biomedicine Birth control Chemical kinetics Chloroquine Chloroquine - adverse effects Clinical trials Compliance Contraindications Controlled human malaria infection Disease prophylaxis Dosage Dosage and administration Drug Combinations Drug dosages Drug Resistance Drug therapy Electrocardiography Entomology Female Human diseases Humans Infections Infectious Diseases Laboratories Malaria Malaria chemoprophylaxis Malaria, Falciparum - drug therapy Male Methods Microbiology Middle Aged Military operations Mosquitoes Nausea Parasites Parasitology Pharmacokinetics Plasmodium falciparum Plasmodium falciparum - drug effects Pregnancy Prophylaxis Public Health Side effects Symptoms Tropical Medicine Vector-borne diseases Weekly Young Adult |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals (ND) dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwEDaoJxBCvAkUZCQkDhDVeflxXBClQgJxKFJvlh3baqRsFm22gu6vZ8ZJlk0RcOEW-RE_Mra_cWa-IeSlBZDhy1ClrA4yLZ3wqVQmS60zipVCFEKgN_Knz_zka_nxrDrbC_WFNmEDPfAwcUfeZa5w3CoJyBcOFIOMYUFwVZlMBhuhEVNsUqbG_wcghvnkIiP5UY-nGhrbspQVoNGk29kxFNn6f9-T9w6lqwaTV_6axsPo-A65PaJIuhh6f5dc9909cmu4gqODZ9H9azcXHcXgWBQ-tG9pJJKlq0AB8tHeBL-5pKZz1COJhKljlqF4ddB66la9x4TvkXCf1ueg1kN3AZLGOmbbYHyF5WXddNSM_LsY9ZMCBqZLA-pyYyiMED5ia340PYVyg8slNIqUHz28cwzj4iheBlPxQe63k659j9i229AvgPCXK9dcLGkwLRqBr-ERW6ajpX0LL4nRBndtT0ZmkIKxfh6Q0-P3p-9O0jH2Q1oDItymIticFbUtrMq5ZVJVwYjaWSs5s6Gw6EELWNBLx3NXuhB4zVwQVchZqEJWPCQH3arzjwlFSFxZWQRUvoIAQIxqZmadE4C1MpOQbJIEXY-86Bieo9VRP5JcD9KjQXp0lB69TcjrXZ1vAyvIX0u_RQHblURG75gAcq5HOdf_kvOEvELx1LjvQPdALgb3CRgkMnjpBS-4KmFaWEIOZyVhv6jn2ZOA63G_6jWAvEJJQOOQ_WKXjTXRBq_zq4uhjBQAp1VCHg3rYTekAsYsy7JMiJitlNmY5zldcx7ZzEWpCtDyE_JmWlO_uvXnOX3yP-b0KbmRxz1BpRk_JAeb9YV_BhhzY5_H7eQnsu59Jw priority: 102 providerName: Directory of Open Access Journals – databaseName: Public Health Database dbid: 8C1 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwEDZQLiCEeBMoyEhIHMBqnrZzQktFqZBAHIrUW2THdhspm5TNrqD765lxHm2K6C3yI7bjmfE3zjwIeasBZNjUZSwsnWSpEZbJXEVMG5WHqRCJEOiN_O07P_yZfj3OjocLt24wqxxlohfUpi3xjnwPjqEkl4AXwo9nvxhmjcK_q0MKjVvkdgQyGBlT7k8mHhEQYzw6yki-1-HZhia3IQsT0GvYdnYY-Zj9_0rmS0fTVbPJK_9O_ZF08IDcH7AkXfSb_5DctM0jcq-_iKO9f9HjG3cXDcUUWRS229bUh5OlraMA_GinnF2fU9UYajGUhCp9laJ4gVBbatrOYsFvH3aflqeg3MN0AZj6PmpbYZaF5XlZNVQNUXgx9ycFJEyXCpTmSlFYIWxlrf5UHYV2veMlDIqBPzp455DMxVC8Eqbii7w8DlvZDhFus6Y_AOcvW1NtltSpGk3BV_CII9PB3r6Gl_icg9PYo6kZlGDGnyfk6ODz0f4hGzJAsBJw4ZYJp-MwKXWi85jrUOaZU6I0Wkseapdo9KMFRGil4bFJjXO8DI0TmYtDl7koeUp2mraxzwlFYJxpmThUwZwAWIzKZqSNEYC4IhWQaKSEohyio2OSjrrwWpLkRU89BVBP4amn2Abk_dTnrI8Ncm3rT0hgU0uM6-0L2tVJMYiJwprIJIbrXIKeB_BJYXw8J3ieqUg6DdN8h-RZoPSB6QFd9E4UsEiM41UseMLzFD5LGJDdWUuQGuW8eiTwYpBaXXHBYwF5M1VjT7TEa2y76dtIAaA6D8iznh-mJSWwZpmmaUDEjFNma57XNNWpj2ku0jwBXT8gH0aeupjW_7_pi-tX8ZLciT235yziu2RnvdrYV4Ah1_q1FxR_ASxFdJ4 priority: 102 providerName: ProQuest – databaseName: SpringerLink Journals (ICM) dbid: U2A link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwEDZQLiCEeBMoyEhIHCAiiRPbOS6IUiGBOLRSb5Yd222kbII2u4Lur2fGedAtD4lbFI9jOx6Pv7HnQchLAyDD5b6Ik8rLOLfCxbLUaWysLpNcCCYEeiN__sIPj_NPJ8XJ6BTWT9bu05VkkNRhWUv-tsedCQ1mkzhhoJXE22vkegG6Oy7H42wx3x0AC2aTe8wf6-1sQSFS_-_y-MKGdNlY8tKNadiIDu6Q2yOCpIthyu-Sq669R24Nx2908Cq6f-XmoqWYGIvCJLuGhiCytPMU4B7ttXfrc6pbSx0GkNBVKNIUjw0aR23XO3zxPQTbp9UZqPTQXYCjoY7e1phbYXle1S3VY-xdzPhJAf_SpQZVudYURggT2OgfdU-BbnC3hEYx3EcP3xxTuFiKB8FUfJQX24lXrkdc267pV0D3y87WmyX1ukED8BU8Yst0tLJv4CMh0-Dc9mRgBm8wz88DcnTw4ej9YTzmfYgrQIPbWHiTJawyzJQZN4ksC69FZY2RPDGeGfSeBRzopOWZza33vEqsF4XPEl_4lD0ke23XuseEIhwujGQeFS8vAAyjipkaawXgrFRHJJ04QVVjTHRMzdGooBtJrgbuUcA9KnCP2kbk9Vzn2xAR5J_U75DBZkqM5h1edKtTNQoH5WxqmeWmlKDdAWjSGBXPC14WOpXeQDdfIXsqlDnQPeCLwXUCBonRu9SCM17m8FuSiOzvUIKsqHaLJwZXo6zqFQA8VkpA4lD8Yi7Gmmh_17puM9BIAVC6jMijYT3MQ2IwZpnneUTEzkrZGfNuSVufhUjmIi8ZaPgReTOtqV_d-vs_ffJ_5E_JjSys_jJO-T7ZW6827hkgybV5HgTHT-vdclQ priority: 102 providerName: Springer Nature |
| Title | An open label study of the safety and efficacy of a single dose of weekly chloroquine and azithromycin administered for malaria prophylaxis in healthy adults challenged with 7G8 chloroquine-resistant Plasmodium falciparum in a controlled human malaria infection model |
| URI | https://link.springer.com/article/10.1186/s12936-020-03409-z https://www.ncbi.nlm.nih.gov/pubmed/32938444 https://www.proquest.com/docview/2443988350 https://www.proquest.com/docview/2443879299 https://pubmed.ncbi.nlm.nih.gov/PMC7493140 https://doaj.org/article/ed1d3d6b98974024a5273f7695a18fba |
| Volume | 19 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1bb9MwFDa7SGgIIe4URmUkJB4gI1fbeUCoqzYmpE0TWqW9RXZss0hpCk0r1v56znGSbh0bL1XrS3zpOfZ3nOPvEPJeAcgwsU08P7fCizU3nkhl4CktUz_mPOIcbyMfn7CjUfz9PDnfIF24o3YC61tNO4wnNZqWe5e_F19B4b84hRfsc417FrrS-p4fgb3iLTfJNuxMDI2x4_jqrQIIZ9hdnLm13g65H0GaiON4bZ9ydP7_LtrXdq2bHpU3Xqu63erwMXnUwkw6aOTiCdkw1VPysDmjo83Vo2f3HgwqiqOlIAmmpI5plk4sBUxIa2nNbEFlpalBlgmZuyxJ8WyhNFRPaoMJfxwjP80vwO6H7gJmdXXkssAADONFXlRUtgS9GBaUAkimYwmTXkgKI4R_uZSXRU2hXHMnExpFTpAantnGedEUT4sp_yaut-NNTY3gt5rRUzABxhNdzMfUyhK9xKfwFVumrSt-CQ9x4QhXbXdeaJCCwYCek7PDg7PhkdcGh_BygIxLj1sV-lGuIpWGTPkiTazkuVZKMF_ZSOEVWwCLRmgW6lhby3JfW57Y0LeJDaIXZKuaVOYVoYiZEyUii9aZ5YCY0Q4NlNYcwFggeyToJCHLW-J0jN9RZs6AEixrBCkDQcqcIGXLHvm4qvOroQ35b-l9FLBVSaT8dgmT6c-sXUEyowMdaaZSASYgICuJ1HmWszSRgbAKuvkBxTNDVYHugVw09ytgkEjxlQ1YxNIYpsXvkd21krCg5OvZnYBnnT5mgAKjVABch-x3q2ysiU56lZnMmzKCA95Oe-Rlow-rIXVq1SN8TVPWxryeUxUXju6cx2kUxNDup06nrrp195y-vrMLb8hO6HQ-9QK2S7Zm07l5C8hypvpkk59z-BTDoE-29w9OTn_AryEb9t1ZTd8tJ_A5Cgd_Ab-ufjE |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFDZjPABCiDuFAUYC8QDRcrfzgFC5jI5dxEOR-mbZsc0qpcloWo32P_EfOcdJunWIve2t8iW208_H33HOhZBXCkiGiW3i-bnlXqyZ8XgmA09pmfkxYxFj6I18cJgOfsTfRslog_zpfGHQrLKTiU5Q6yrHO_JtOIaijANf8D8c__IwaxR-Xe1SaDSw2DOLE1DZ6ve7n-H_fR2GO1-GnwZem1XAy4FrLD1mVehHuYpUFqbK51liJcu1Ujz1lY0U-mYCyzBcp6GOtbVp7mvLEhv6NrFBBI-9Sq7FeDEO24eNVvpdANgPO78cnm7XeJSiha_v-RGoUd5y7exzKQL-PQjOnITnrTTPfap1J-DOHXK7pa6032DtLtkw5T1yq7n3o4070_0rN_slxYxcFNBlCuqi19LKUuCZtJbWzBZUlpoajFwhc1clKd5XFIbqqjZYcOKi_NP8qKhwusCDXR-5HGNSh8kiH5dUtkF_MdUoBeJNJxJ09LGksEJATiF_j2sK7Ro_TxgU44zU8Mw2d4ymeANN2Vd-dhxvamok1OWMfge1YlLp8XxCrSzQ8nwKP3Fk2pr3F_AQl-JwNXZn2QYlmGDoARleBjQeks2yKs1jQpGHJ4pHFjU-y4CFo24bKK0ZELxA9kjQIUHkbTB2zAlSCKeU8VQ06BGAHuHQI5Y98nbV57gJRXJh648IsFVLDCPuCqrpT9FKJWF0oCOdqoyDWglsTWI4PsvSLJEBtwqm-QbhKVDYwfQAF43PBiwSw4aJfhqlWQyvxe-RrbWWIKTy9eoO4KIVkrU43dI98nJVjT3R8K801bxpwxlw-KxHHjX7YbWkCNbM4zjuEba2U9bWvF5Tjo9cCHUWZ1EQw7jvuj11Oq3_v9MnF6_iBbk-GB7si_3dw72n5Ebodn7mBekW2ZxN5-YZ0NeZeu6EBiXikoXUX-q-skY |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Zb9QwEDZQJARCiJuFAkZC4oFGzWk7j0uhlKvqQ5H6ZtmxTSNls9VmV9D99cw4B5tySLxFsR3byXj8TTzzDSEvNYAMm7osCAsngtRwG4hcRYE2Kg9TzhPOMRr5yyE7-Jp-PMlONqL4vbd7fyTZxjQgS1O93D0zrl3igu02uEuh82wYhAlYKMH6Crma4taHx7VsbzhHAHGM-1CZP7YbbUeetf933byxOV10nLxweuo3pf3b5FaHJum0_fx3yGVb3yU3219xtI0wunfpxrSmmCSLwge3FfWEsnTuKEA_2ihnl-dU1YZaJJNQhS9SFH8hVJaaeWPxxndPvE-LUzDvYbgATX0btS4xz8LsvChrqjoeXsz-SQEL05kCs7lUFGYIH7NSP8qGQr029BI6ReqPBp7ZpXMxFH8KU_5ebPYTLGyDGLde0iNA-rO5KVcz6lSFzuALuMSeaedxX8FDfNbBoe_e2QzuYM6f--R4_93x3kHQ5YAICkCG64A7HYdJoROdx0yHIs-c4oXRWrBQu0RjJC1gQisMi01qnGNFaBzPXBy6zEXJA7JVz2v7iFCExpkWiUMjzHEAxmhuRtoYDpgrUhMS9ZIgi44fHdN0VNLbSYLJVnokSI_00iPXE_J6aHPWsoP8s_YbFLChJjJ7-xvzxTfZKQppTWQSw3QuwNIDAKWQIc9xlmcqEk7DMF-heErUPzA8kIs2jAImiUxecsoSlqfwWsIJ2R7VBL1RjIt7AZed3mokgL0kF4DKofjFUIwt0RevtvNVW0dwgNX5hDxs18MwpQTmLNI0nRA-WimjOY9L6vLUs5rzNE_A2p-QnX5N_RrW39_p4_-r_pxcO3q7Lz9_OPz0hFyPvSLIg4htk63lYmWfAsBc6mdeh_wEasd5bQ |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=An+open+label+study+of+the+safety+and+efficacy+of+a+single+dose+of+weekly+chloroquine+and+azithromycin+administered+for+malaria+prophylaxis+in+healthy+adults+challenged+with+7G8+chloroquine-resistant+Plasmodium+falciparum+in+a+controlled+human+malaria+infection+model&rft.jtitle=Malaria+journal&rft.au=Livezey%2C+Jeffrey&rft.au=Twomey%2C+Patrick&rft.au=Morrison%2C+Meshell&rft.au=Cicatelli%2C+Susan&rft.date=2020-09-16&rft.eissn=1475-2875&rft.volume=19&rft.issue=1&rft.spage=336&rft_id=info:doi/10.1186%2Fs12936-020-03409-z&rft_id=info%3Apmid%2F32938444&rft.externalDocID=32938444 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1475-2875&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1475-2875&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1475-2875&client=summon |